ADEXUSDx® COVID-19 Test Receives Conformité Européene (CE) Mark Approval

ADEXUSDx® COVID-19 Test Receives Conformité Européene (CE) Mark Approval

ADEXUSDx COVID-19 Test receives Conformité Européene (CE) mark approval

We are proud to announce that our ADEXUSDx COVID-19 antibody test has received Conformité Européene (CE) mark approval across 28 countries in the EU. With CE approval, our antibody test will be available in a variety of healthcare centers such as clinics and hospital emergency rooms.

Our ADEXUSDx COVID-19 Test is a rapid serology, self-contained assay that measures the presence of SARS-CoV-2 antibodies and delivers accurate and reliable results in 15 minutes with no buffers, reagents, or additional equipment.

Made in the USA, The ADEXUSDx® COVID-19 Test uses an FDA-cleared and CE-marked platform containing next-generation, easy-to-use technology that is affordable, portable, and delivers laboratory-quality results in minutes without any additional supplies.

Interested in learning more? You can read the full article here.

NOWDiagnostics, Inc., based in Springdale, Arkansas, is a leader in innovative diagnostics testing. Its ADEXUSDx® product line features a lab at your fingertip, using a single drop of blood to test for a variety of common conditions, illnesses, and diseases, with results in a matter of minutes. By eliminating the need to send tests to off-site laboratories, NOWDiagnostics products have the potential to decrease the waiting period to determine test results by days. For more information about NOWDiagnostics, visit For more information about the ADEXUSDx® COVID-19 Test, including its intended use, features, benefits and limitations, and directions for use, visit The ADEXUSDx® COVID-19 Test will be distributed by C19 Development, LLC, a wholly owned subsidiary of NOWDiagnostics. Laboratories may contact to place an order.


NOWDiagnostics Company Contact
Beth Cobb, Director of Operations

NOWDiagnostics Media Contact
Claire Burghoff, CGA Group